WHO ICTRP trial
A phase Ib/II study investigating the combination of RAD001 with trastuzumab and…
NL-OMON35692 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON35692 |
|---|---|
| Public title | A phase Ib/II study investigating the combination of RAD001 with trastuzumab and paclitaxel in patients with HER2-overexpressing metastatic breast cancer. |
| Scientific title | A phase Ib/II study investigating the combination of RAD001 with trastuzumab and paclitaxel in patients with HER2-overexpressing metastatic breast cancer. - HER2+ MBC, RAD001 + trastuzumab+ paclitaxel. |
| Primary sponsor | Novartis |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | Netherlands |
| Conditions | Breast cancer;10027656;Breast cancer |
| Interventions | Patients will be instructed to use RAD001 10 mg daily dose. Tablets contain 2,5 / 5 / 10 mg each. ;HER2-positive;metastatic breastcancer;RAD001 |
| Registration date | Feb 11, 2010 |
| Target size | 5 |
| Secondary IDs | 2006-001596-37;NCT00426556;NL25462.068.08 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: